U. N. Mehta · founded 1959 · Ahmedabad, India
Torrent Pharmaceuticals
An Ahmedabad, family-promoted company that grew from a 1959 founder bet into a roughly ₹11,500 crore domestic-led franchise, built as much by acquisition as by launch.
With a third-generation Managing Director appointed in 2025, the question is whether the inherited Elder, Unichem domestic and Curatio portfolios run as one coordinated engine rather than a federation of legacy brands.
1959
Founded
Who founded Torrent Pharmaceuticals and when?
U. N. Mehta founded it in 1959 as Trinity Laboratories in Ahmedabad with about ₹25,000 of seed capital, after 14 years as a Sandoz medical representative. Renamed Torrent Pharmaceuticals in 1971.
How big is Torrent today?
Per the audited FY2025 results, revenue was about ₹11,516 crore and net income about ₹1,911 crore, operating in more than 40 countries with over 2,000 product registrations.
What were its biggest acquisitions?
Elder Pharmaceuticals' India formulations (2013, about ₹2,004 crore), Unichem Laboratories' domestic business (2017, about ₹3,600 crore) and Curatio Healthcare skincare (2022, about ₹2,000 crore).
Why does Torrent matter as a commercial-intelligence example?
Three large acquired domestic franchises sit on top of the core cardiovascular and CNS business; running them as one engine instead of inherited federations is the binding constraint.
Key takeaways
Origin
In 1959, a 35-year-old medical representative who had spent 14 years walking doctors' chambers for Sandoz left and started his own company. U. N. Mehta founded Trinity Laboratories in Ahmedabad with about ₹25,000 of his own money. That ordinary-looking decision was the start of Torrent.
Renamed Torrent Pharmaceuticals in 1971, the founder's instinct that an Indian field rep could read prescription markets better than imported playbooks became the company's commercial DNA: detailing depth in cardiovascular and central nervous system, chronic-care strength in gastrointestinal and diabetology, run from Ahmedabad.
Built as much by acquisition as by launch
The 1997 Sanofi joint venture was an early distribution experiment; Torrent exited in 2002, choosing operational control over multinational cover, a pattern that recurred. Europe came via the 2005 Heumann Pharma acquisition from Pfizer. The defining moves were domestic: Elder Pharmaceuticals' India formulations (2013, ₹2,004 crore), Unichem's domestic business (2017, ₹3,600 crore, its largest), and Curatio Healthcare skincare (2022, ₹2,000 crore). Three franchises, three integration projects, three field-force cultures absorbed.
Why the commercial engine is the interesting part
By FY2025 Torrent reports revenue of about ₹11,516 crore on net income of about ₹1,911 crore, operating in 40-plus countries. Each acquired franchise came with its own field force, detailing rhythm and brand bench. Integration without dilution is harder than the announcement suggests: coverage discipline has to be consistent across legacy and inherited divisions, and quality and regulatory discipline continuous across a global API supply chain, as the industry-wide valsartan and losartan recalls of 2018 to 2019 made visible.
The next chapter
On 20 May 2025 Torrent confirmed a generational handover: Aman Mehta as Managing Director, Samir Mehta as Chairman. The question the market watches is coordination, not strategy: whether the three acquired domestic businesses settle into one coherent commercial engine and whether Curatio grows at a rate worth the price paid.
It will not be more dashboards. The next advantage is intelligence: every rep knowing which prescriber on an inherited brand slipped this fortnight, every divisional head separating a market shift from integration drag in time to act, leadership acting on the few decisions that move the quarter. The first generation of Indian pharma built access. The second built scale. The next will build intelligent commercial operations. That is the future PharmaOS is built for.
Torrent Pharmaceuticals
1959
Founded
Commercial engine
Therapy areas
Cardiovascular, central nervous system, gastrointestinal, diabetology and anti-infectives as anchors, plus skincare via the 2022 Curatio acquisition.
Field force
A multi-division Indian field force extended via three large acquisitions, plus a regulated and emerging-markets export presence across 40-plus countries.
Doctor engagement
Specialist and high-volume prescriber engagement in cardiovascular, CNS and gastrointestinal, with chronic-care depth that survives the Elder and Unichem integrations.
Flagship brands
A portfolio assembled organically and through Elder (2013), Unichem domestic (2017) and Curatio (2022); international products via the Heumann Pharma channel in Germany since 2005.
Distribution
Domestic-led footprint plus 2,000-plus product registrations across 40-plus countries; Heumann anchors regulated-market exposure.
Execution complexity
Integrating three large acquired domestic businesses without diluting the core, while sustaining continuous quality and regulatory discipline in an export-led generics supply chain.
Timeline
U. N. Mehta founds Trinity Laboratories in Ahmedabad with about ₹25,000.
A Sandoz field rep bets his career on building an Indian pharma company at 35.
Trinity Laboratories is renamed Torrent Pharmaceuticals.
The umbrella identity for the wider Torrent Group.
Acquires the domestic business of Unichem Laboratories for about ₹3,600 crore.
The largest formulations acquisition; materially deepens chronic-care mix.
Aman Mehta appointed Managing Director on 20 May.
Generational handover; the market watches for continuity of strategy.
If it were built today
Every cardiovascular or CNS rep would walk into a call already knowing which doctor on the inherited Elder or Unichem franchise slipped this fortnight, and against which competitor.
Every divisional head would see whether month-end variance was a coverage gap, a price-volume shift, or integration lag from an acquired franchise, with the cause isolated.
Every brand manager on the Curatio paediatric dermatology portfolio would see whether growth came from prescriber switching, channel shift or campaign effect, the same week.
Leadership would act on the two or three coverage and integration decisions that move the quarter, not review nine therapy areas in dashboards.
Stock and event snapshot
LoadingPharmaOS reading
A domestic-led, acquisition-built portfolio with steady operating leverage. The next decade is decided less by category growth and more by how coherently the inherited franchises are run as one commercial engine.
This is market commentary for business and industry analysis only. It is not investment advice, research advice or a recommendation to buy, sell or hold any security.
The PharmaOS point of view
The next advantage in pharma is decision intelligence, not a larger field force or more dashboards.
The first generation of Indian pharma built access. The second built scale. The next will run on commercial intelligence: every rep, manager and brand head acting on the real reason, in time to change the outcome.
Continue
See the operating intelligence layer.
A 20-minute private walkthrough on a slice of your own commercial data. Nothing migrated, nothing stored.
FAQ
No. Independent commentary written only from public sources for business analysis. It implies no endorsement or commercial relationship.
From Torrent's public FY25 press release and audited results, its public Our Story page, mainstream coverage of the May 2025 MD appointment, and Wikipedia. Sources are listed below.
No. The reading is qualitative business interpretation only. It is not investment, research or trading advice, and no target price or directional call is offered.
Pharma's next advantage is decision intelligence across reps, managers and brands, not a larger field force or more dashboards.
Sources
- 01Wikipedia: Torrent Pharmaceuticals. en.wikipedia.org (accessed 2026-05-19)
- 02Torrent Pharma: Our Story. torrentpharma.com (accessed 2026-05-19)
- 03Torrent Pharma: consolidated results, year ended 31 March 2025. torrentpharma.com (accessed 2026-05-19)
- 04Economic Times: Aman Mehta appointed Managing Director of Torrent Pharma (20 May 2025). economictimes.indiatimes.com (accessed 2026-05-19)